Section Arrow
APGE.NASDAQ
- Apogee Therapeutics
Quotes are at least 15-min delayed:2025/11/04 04:20 EST
Pre Market
Last
 55
+0.65 (+1.20%)
Bid
45.53
Ask
63
High 55 
Low 55 
Volume 25 
Regular Hours
Last
 54.35
-2.24 (-3.96%)
Day High 
58.36 
Prev. Close
56.59 
1-M High
57.63 
Volume 
774.48K 
Bid
45.53
Ask
63
Day Low
53.53 
Open
56.98 
1-M Low
38.88 
Market Cap 
3.83B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 55.44 
20-SMA 52.88 
50-SMA 43.92 
52-W High 63.5 
52-W Low 26.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.14/-5.14
Enterprise Value
3.84B
Balance Sheet
Book Value Per Share
9.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
Pre Market 1.67 -0.19 -10.22%
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
Pre Market 2.37 -0.06 -2.47%
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
Pre Market 1.975 +0.025 +1.28%
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
Pre Market 5.28 -0.16 -2.94%
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Pre Market 3.14 -0.06 -1.88%
Quotes are at least 15-min delayed:2025/11/04 04:20 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.